Beam Therapeutics Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Yahoo! Finance
Beam Therapeutics Inc. Q4 2025 Earnings Call Summary - Moby Strategic Rationale and Platform Scalability The new BEAM-304 program for Phenylketonuria (PKU) serves as a strategic expansion of the liver-targeted portfolio, utilizing the same clinically validated LNP delivery system as prior programs. Management attributes the selection of PKU to its high addressability via base editing, as the disease is primarily caused by single-point mutations in hepatocytes reachable by LNPs. The platform's modularity allows for a 'flywheel' effect where only the guide RNA needs to be changed to address different mutations, significantly reducing incremental R&D costs and development risk. Strategic positioning focuses on the 'power of predictability,' aiming for reproducible outcomes across a growing pipeline rather than relying on a single-asset success story. Operational efficiency is driven by internal GMP manufacturing capabilities in North Carolina, which support the transition fr
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics (BEAM) had its price target raised by Royal Bank Of Canada from $22.00 to $26.00. They now have a "sector perform" rating on the stock.MarketBeat
- Beam Therapeutics (BEAM) had its price target raised by Wedbush from $57.00 to $65.00. They now have an "outperform" rating on the stock.MarketBeat
- Beam Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)GlobeNewswire
- Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth StreetGlobeNewswire
BEAM
Earnings
- 2/24/26 - Beat
BEAM
Sec Filings
- 2/24/26 - Form 144
- 2/24/26 - Form S-8
- 2/24/26 - Form 10-K
- BEAM's page on the SEC website